Shattuck Labs Announces Positive Phase 1 Results for SL-325 DR3 Antibody in Crohn’s Disease, Plans Phase 2b Trial in 2026
Shattuck Labs Announces Promising Phase 1 Results for SL-325...
Sign in to continue:
Shattuck Labs Announces Promising Phase 1 Results for SL-325...
Interactive Strength Inc. (NASDAQ: TRNR) Announces Results o...
Revolve Group, Inc. 8-K Report: Key Details from the June 20...
MoonLake Immunotherapeutics 8-K Report - Detailed Investor U...
Adaptive Biotechnologies Corporation Announces Results of 20...
Brookfield Asset Management Ltd. Files Form 8-K: Key Highlig...
Humacyte, Inc. 8-K Filing: Key Updates for Investors H...
Flag Ship Acquisition Corp. Regains Nasdaq Compliance ...
Eureka Acquisition Corp Receives Nasdaq Delisting Notificati...
Fifth Third Bancorp Releases Investor Presentation at Morgan...